Showing results (241-250 of 318) with videos related to
Sort By:
Pageof 32
Plos One|January 17, 2023
Immune-related pan-cancer gene expression signatures of patient survival revealed by NanoString-based analysesAlberto D'Angelo, Huseyin Kilili, Robert Chapman, et al.The Oncologist|August 23, 2024
Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational studyFrancesco Schettini, Marianna Sirico, Marco Loddo, et al.Targeted Oncology|September 24, 2022
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 StudyMichelino De Laurentiis, Roberta Caputo, Manuelita Mazza, et al.ESMO Open|November 6, 2020
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trialMatteo Lambertini, Dominique Agbor-Tarh, Otto Metzger-Filho, et al.Journal of the National Cancer Institute|May 15, 2020
Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-AnalysisFrancesco Schettini, Fabiola Giudici, Mario Giuliano, et al.International Journal of Cancer|November 15, 2019
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trialMatteo Lambertini, Francesca Poggio, Marco Bruzzone, et al.Cancer Treatment Reviews|September 29, 2024
The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancerFederico Rebaudi, Fabiana De Franco, Rayan Goda, et al.Plos One|August 8, 2019
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE studySerena Di Cosimo, Nicla La Verde, Anna Moretti, et al.Breast Cancer Research and Treatment|January 29, 2014
Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy"Chiara Foroni, Manuela Milan, Carla Strina, et al.JNCI Cancer Spectrum|August 12, 2025
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysisFrancesco Schettini, Sabrina Nucera, Giuseppe Di Grazia, et al.Pageof 32